Drug Trial Radar · NCT01120691
Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations
Last checked: Nov 19, 2026Latest source record: Dec 2, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,224
Actual
Start
Apr 2010
Primary completion
Jul 2012
Study completion Jul 2012
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 11, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to assess the effect of once-daily QVA149 on COPD exacerbations in patients with severe to very severe COPD.
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
QVA149Drug
QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
NVA237Drug
NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
tiotropiumDrug
Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
Salbutamol/albuterolDrug
As needed throughout the study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in QVA149 and NVA237 Treatment Arms During the Treatment Period.Time frame: 64 weeks
Locations
342 sites in 28 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Birmingham, Alabama
Novartis Investigative Site
Fairhope, Alabama
Novartis Investigative Site
Florence, Alabama
Novartis Investigative Site
Homewood, Alabama
Novartis Investigative Site
Jasper, Alabama
Novartis Investigative Site
Pine Bluff, Arkansas
Novartis Investigative Site
Fullerton, California
Novartis Investigative Site
Palo Alto, California
Novartis Investigative Site
Riverside, California
Novartis Investigative Site
San Diego, California
Novartis Investigative Site
San Diego, California
Novartis Investigative Site
San Diego, California
Novartis Investigative Site
Stockton, California
Novartis Investigative Site
Gainesville, Florida
Novartis Investigative Site
Miami, Florida
Novartis Investigative Site
Pensacola, Florida
Novartis Investigative Site
Couer D'Alene, Idaho
Novartis Investigative Site
Normal, Illinois
Novartis Investigative Site
River Forest, Illinois
Novartis Investigative Site
Florence, Kentucky
Novartis Investigative Site
Louisville, Kentucky
Novartis Investigative Site
Opelousas, Louisiana
Novartis Investigative Site
Bangor, Maine
Novartis Investigative Site
Fridley, Minnesota
Novartis Investigative Site
Ozark, Missouri
Novartis Investigative Site
Saint Charles, Missouri
Novartis Investigative Site
St Louis, Missouri
Novartis Investigative Site
Missoula, Montana
Novartis Investigative Site
Papillion, Nebraska
Novartis Investigative Site
Henderson, Nevada
Novartis Investigative Site
Las Vegas, Nevada
Novartis Investigative Site
Reno, Nevada
Novartis Investigative Site
Great Neck, New York
Novartis Investigative Site
Massapequa, New York
Novartis Investigative Site
Charlotte, North Carolina
Novartis Investigative Site
Raleigh, North Carolina
Novartis Investigative Site
Wilmington, North Carolina
Novartis Investigative Site
Columbus, Ohio
Novartis Investigative Site
Medford, Oregon
Novartis Investigative Site
Portland, Oregon
Showing 40 of 342 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.